Data from Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial

相关 签名(拓扑) 软组织肉瘤 肉瘤 软组织 医学 肿瘤科 内科学 计算机科学 病理 数学 哲学 语言学 几何学
作者
David S. Moura,Jesús M. López Martí,Iva Benešová,Carlos E. de Andrea,Davide di Lernia,Serena Lacerenza,José L. Mondaza-Hernández,Marta Martín‐Ruiz,Marta Ramírez-Calvo,Giovanni Grignani,Javier Martínez‐Trufero,Andrés Redondo,Claudia Valverde,Silvia Stacchiotti,Antonio López‐Pousa,José Antonio López‐Guerrero,Antonio Gutiérrez,Victor Encinas-Tobajas,Nadia Hindi,Dario Sangiolo,José A. López-Martín,Zuzana Střížová,Javier Martín‐Broto
标识
DOI:10.1158/1078-0432.c.7541193
摘要

<div>Purpose:<p>The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial.</p>Experimental Design:<p>Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline and week 13. Formalin-fixed paraffin-embedded samples were used for transcriptomics and multiplex immunofluorescence, whereas peripheral blood samples were used for multiplexed immunoassays. Flow cytometry and Luminex assays were performed to validate translational findings in tumor-isolated cells and peripheral blood mononuclear cells derived from patients.</p>Results:<p>The density of intratumoral CD8<sup>+</sup> T cells, measured by multiplexed immunophenotyping, was significantly increased after treatment. This augment was accompanied by the dynamic significant increase in the gene expressions of <i>CD86</i>, <i>CHI3L1</i>, <i>CXCL10</i>, <i>CXCL9</i>, <i>LAG3</i>, and <i>VCAM1</i> and the decrease in the expression levels of <i>NR4A1</i>. In peripheral blood, 12 proteins were significantly modulated by treatment at week 13. A score integrating the dynamic expression of the 7 genes and the 12 soluble factors separated 2 groups with distinct progression-free survival (PFS): 4.1 months [95% confidence interval, 3.5–not reached (NR)] versus 17 months (95% confidence interval, 12.0–NR), <i>P</i> = 0.014. This molecular score was predictive of PFS when applied to the normalized data determined in the baseline samples.</p>Conclusions:<p>Treatment with sunitinib and nivolumab inflamed the sarcoma microenvironment, increasing CD8<sup>+</sup> T-cell density and the expression of several genes/proteins with relevance in the response to PD1 inhibitors. A molecular signature identified two groups of patients with distinct PFS for the combination of antiangiogenics plus PD1 inhibitor therapy.</p></div>
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沈ff发布了新的文献求助10
1秒前
朴实的绣连完成签到,获得积分10
1秒前
3秒前
牧歌发布了新的文献求助30
3秒前
QQiang6发布了新的文献求助10
4秒前
5秒前
孟欣玥发布了新的文献求助10
5秒前
机灵的囧完成签到,获得积分10
6秒前
llll发布了新的文献求助10
6秒前
8秒前
9秒前
11秒前
TMX完成签到,获得积分20
11秒前
soldatJiang发布了新的文献求助10
12秒前
NL14D发布了新的文献求助10
12秒前
wq1020完成签到,获得积分10
12秒前
12秒前
科研通AI5应助孟欣玥采纳,获得20
13秒前
13秒前
Ava应助什么东西这么好看采纳,获得10
13秒前
超级丝发布了新的文献求助10
13秒前
TMX发布了新的文献求助10
16秒前
星星完成签到,获得积分10
16秒前
wenbinvan完成签到,获得积分0
16秒前
18秒前
科研通AI2S应助SAVP采纳,获得10
18秒前
Lycerdoctor发布了新的文献求助10
18秒前
李健应助wudan采纳,获得10
19秒前
19秒前
ANmin发布了新的文献求助10
19秒前
Inory007发布了新的文献求助10
20秒前
20秒前
桐桐应助冰棍采纳,获得10
20秒前
牧歌完成签到,获得积分0
20秒前
烟花应助怡然的一斩采纳,获得10
20秒前
21秒前
21秒前
SciGPT应助Nxxxxxx采纳,获得10
21秒前
22秒前
丘比特应助汪汪采纳,获得10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028